Tests esketamine infusion for chronic pelvic pain from endometriosis
Compares an 8-hour esketamine infusion with a saline placebo in adults with endometriosis pain.
Key facts
- Who runs it
- Reinier de Graaf Groep
- Where
- Delft, NetherlandsSee the site
- Trial code
- Registry title
- EASYlight study
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 56 people, planned
- Started
- 14 Feb 2024
- Planned end
- 8 Jan 2025
- Type of study
- Interventional
- Record updated
- 5 July 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women before menopause who have endometriosis with long-lasting pelvic pain. It tests esketamine given by infusion against a saline placebo.
- Age
- 18 to 64 years. The record also says women above 18 years.
- Sex
- Women only.
- Disease stage
- Endometriosis confirmed by ultrasound, MRI or earlier surgery, in the places listed in the Enzian classification. Pelvic pain of 6 or more on a 0 to 10 scale. An indication for endometriosis surgery, or on the waiting list for it.
- Earlier treatment
- Pain not relieved by paracetamol or NSAIDs. No strong opioids, or stopped for more than 1 week. No change in hormone treatment in the last 1 month.
Main reasons for not taking part
- Pain score below 6 out of 10
- Strong opioid use
- Epilepsy, glaucoma or thyroid disease
- Heart failure, unstable angina or earlier stroke
- Past psychiatric illness, alcohol or drug abuse, cancer, or trying to get pregnant or breastfeeding
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- All pre-menopausal women aged above 18 years
- Women (endometriosis is a condition exclusive to females)
- Diagnosed with endometriosis (ultrasound, MRI or previous laparoscopic and/or diagnostic surgery) according to the #Enzian classification. This means that endometriosis is present in the following compartments: Rectovaginal space (minimal A1) and/or Sacrouterine ligaments, cardinal ligaments, pelvic sidewall (minimal B1) and/or Rectum (minimal C1) and/or Endometriosis of the intestines, diaphragm and/or Adenomyosis (according to the morphological uterus sonographic assessment (MUSA) or evident adenomyosis on the MRI) and/or Peritoneal / superficial endometriosis (diagnosed laparoscopically and not treated during surgery); -Mild to severe chronic pelvic pain (NRS scale >= 6). The 11-point NRS scale ranges from ‘0’ representing no pain to ‘10’ representing the worst pain imaginable; -Resistant to current recommended lines of analgesics (paracetamol, NSAIDs); -Usage of strong opioids must not have been prescribed or otherwise have been discontinued for more than 1 week; -An indication for endometriosis resection surgery or on the waiting list for surgical treatment; -Ability to understand the patient information letter and to give oral and written informed consent; -No alteration in the utilization of hormonal therapy ≤1 months prior to inclusion
Who cannot take part
- Usage of strong opioid medication
- Mentally incompetent (patients not able to make decisions that are in their best interests, this will be evaluated by their treating physician (e.g. patients with an intellectual disability or mental retardation)); -Alcohol or drug abuse
- Unstable angina, heart failure, history of cerebral vascular accident (CVA)
- Patients suffering from an active infection
- Patients with epilepsy
- Poorly regulated hypertension, >180/100mmHg at rest
- Patients with thyroid disease
- Patients with cancer
- History of psychiatric illness (schizophrenia, psychosis, delirium, manic depression)
- Serious medical disease (e.g., cardiovascular, renal , pulmonary or liver disease)
- Severe liver disease
- Endometriosis affecting the bladder and ureter; -Patient with a known (es)ketamine allergy; -Abnormal liver enzyme levels at baseline (ASAT, ALAT, GGT, AF, Bilirubin total), defined in protocol V4
- Pain score <6 out of 10 (NRS) for chronic pelvic pain
- Patients with glaucoma
- Usage of xanthine derivatives or ergometrine
- Patients trying to achieve pregnancy and or patients who are breastfeeding
- Not being able to answer questionnaires (in Dutch)
- Increased intracranial pressure
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Reinier de Graaf GroepDelft, NetherlandsTaking people
About the trial
What the trial wants to find out
The primary aim of the EASYlight study is to assess the effect of 8 hour esketamine infusion versus placebo (saline) on the numeric rating scale score (NRS score) for chronic pelvic pain in patients with chronic pain associated with endometriosis.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Esketamine As treatment for chronic pain due to endometrioSis: a RCT studY
- Plain-language title
- Tests esketamine infusion for chronic pelvic pain from endometriosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2023-508417-16-00, who can take part
- Record updated
- 5 July 2024